Scilex Holding's (SCLX) Scilex Bio venture with IPMC said Wednesday it is enrolling patients with Alzheimer's disease showing mild cognitive impairment and mild dementia in the phase 2 study of KDS2010.
The company is currently enrolling 114 subjects in South Korea and enrollment of the US cohort will begin in 2025, Scilex Bio said.
Scilex Bio said it will evaluate the safety and efficacy of the drug in the randomized, double-blind, placebo-controlled study.
IPMC is a representative company of the Bio Innovation Consortium, which holds exclusive rights to NeuroBiogen's KDS2010 global license.
Price: 0.56, Change: -0.01, Percent Change: -2.59
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。